Get Ahead with IPO Insights, IPO Prophet

IPO Prophet

Get Ahead with IPO Insights

At IPO Prophet®, our team leverages over three decades of expertise to deliver actionable quantitative analytics for the IPO market in real-time. This platform synthesizes our extensive experience investing in IPOs, providing investors with revolutionary tools to navigate the complexities of issuance day. Our mission is to empower investors with data-driven insights to make more informed decisions.

Equity Capital Markets

<ul><li>✓ IPO Prophet Rating: 8.12/10 🏦 Deal Quality &amp; Underwriters: 8.25/10 Oura is offering 50.00 million shares at $40.00 to $44.00 per share, representing a $2.00 billion to $2.20 billion transaction and a fully diluted valuation of approximately $14.2 billion to $15.6 billion.</li><li>The offering is expected to price on September 30, 2026 and trade on Nasdaq under OURA.</li><li>The underwriting syndicate is led by Goldman Sachs, Morgan Stanley, J.P. Morgan, Allen &amp; Company and Jefferies, giving Oura premier consumer-technology and institutional distribution.</li></ul>

✓ IPO Prophet Rating: 8.12/10 🏦 Deal Quality &amp; Underwriters: 8.25/10 Oura is offering 50.00 million shares at $40.00 to $44.00 per share, representing a $2.00 billion to $2.20 billion transaction and a fully diluted valuation of approximately $14.2 billion to $15.6 billion.The offering is expected to price on September 30, 2026 and trade on Nasdaq under OURA.The underwriting syndicate is led by Goldman Sachs, Morgan Stanley, J.P. Morgan, Allen &amp; Company and Jefferies, giving Oura premier consumer-technology and institutional distribution.

<ul><li>Oura Inc. (OURA) plans to offer 50.0 million shares on the Nasdaq Global Select Market at $40 to $44 per share, a $2.1 billion offering at the midpoint.</li><li>Goldman Sachs, Morgan Stanley, J.P. Morgan, Allen &amp; Company, and Jefferies lead the underwriting group.</li><li>The company’s growth makes this one of the more closely watched consumer IPOs, but it also invites a familiar question: Is Oura becoming a lasting part of people’s lives, or is the smart ring having its moment?</li></ul>

Oura Inc. (OURA) plans to offer 50.0 million shares on the Nasdaq Global Select Market at $40 to $44 per share, a $2.1 billion offering at the midpoint.Goldman Sachs, Morgan Stanley, J.P. Morgan, Allen &amp; Company, and Jefferies lead the underwriting group.The company’s growth makes this one of the more closely watched consumer IPOs, but it also invites a familiar question: Is Oura becoming a lasting part of people’s lives, or is the smart ring having its moment?

Oura (OURA) IPO: The Next Health Platform—or the Next Fitbit?

<ul><li>Oura, Inc. plans to sell 50.0 million shares at an expected price of $40.00 to $44.00 per share and list on the Nasdaq Global Select Market under the ticker OURA.</li><li>At the $42.00 midpoint, the offering would raise approximately $2.10 billion and value the company at approximately $13.48 billion.</li><li>Goldman Sachs, Morgan Stanley and J.P. Morgan are leading the offering. </li></ul>

Oura, Inc. plans to sell 50.0 million shares at an expected price of $40.00 to $44.00 per share and list on the Nasdaq Global Select Market under the ticker OURA.At the $42.00 midpoint, the offering would raise approximately $2.10 billion and value the company at approximately $13.48 billion.Goldman Sachs, Morgan Stanley and J.P. Morgan are leading the offering. 

Oura (OURA) IPO: Three Numbers Investors Should Watch

US IPOs and Secondary Offerings, IPO Boutique

IPO Boutique

US IPOs and Secondary Offerings

For more than 20 years, we have been providing research, analysis, commentary and ratings on US Equity Capital Markets to institutional investors (US IPOs and Secondary Offerings). Our vast network of contacts across the Equity Capital Markets and attention-to-detail sets us apart from our competitors.

Since 2012, we have achieved a successful hit rating on 89% of Buy-rated IPOs. The collective “Buy” ratings averaged a first trade of 16.3% above issue.Our Neutral Rated Deals averaged just 2% above the issue price at first trade.

Our written research includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

In addition, we provide a high-touch premium desk access which includes analyst access, as well as real time insights on US IPOs as well as secondary offerings.

IPOs and Secondary Offerings

<ul>
<li>Oura brings a compelling mix of 74% revenue growth, 5.0 million paid members, strong retention and recurring subscription revenue to the IPO market.</li>
<li>Cornerstone interest from Eli Lilly and Dragoneer adds another notable dimension to an offering targeting a valuation above $14 billion.</li>
<li>With Oura serving as the first major technology IPO test after Labor Day, investor demand and pricing will be closely watched.</li>
</ul>


Oura brings a compelling mix of 74% revenue growth, 5.0 million paid members, strong retention and recurring subscription revenue to the IPO market.
Cornerstone interest from Eli Lilly and Dragoneer adds another notable dimension to an offering targeting a valuation above $14 billion.
With Oura serving as the first major technology IPO test after Labor Day, investor demand and pricing will be closely watched.


Oura (OURA US): Oura Steps Into the IPO Spotlight, Sets Terms With $14B+ Valuation Target

<ul>
<li>Biotech remains the IPO market’s lone bright spot, with TRex Bio testing investor appetite as broader September IPOs struggled and Oura postponed. </li>
<li>TRex Bio is seeking $117–$133 million at a $384–$439 million valuation, backed by a Phase 1 lead program and a Lilly collaboration. </li>
<li>Lilly provides a significant validation signal, with a 23.9% pre-IPO stake and TRex Bio eligible for up to $577.5 million in additional milestones plus royalties.</li>
</ul>


Biotech remains the IPO market’s lone bright spot, with TRex Bio testing investor appetite as broader September IPOs struggled and Oura postponed. 
TRex Bio is seeking $117–$133 million at a $384–$439 million valuation, backed by a Phase 1 lead program and a Lilly collaboration. 
Lilly provides a significant validation signal, with a 23.9% pre-IPO stake and TRex Bio eligible for up to $577.5 million in additional milestones plus royalties.


TRex Bio (TRXB): Biotech Sector Remains Open as Lilly Backed Bio Sets Terms for IPO

United States

Oura Health is a Finnish health technology company best known for creating the Oura Ring, a leading wearable smart ring.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Oura (OURA US)

IPO Rating: ŌURA Inc.

✓ IPO Prophet Rating: 8.12/10 🏦 Deal Quality & Underwriters: 8.25/10 Oura is offering 50.00 million shares at $40.00 to $44.00 per share,...

IPO Prophet

Oura (OURA) IPO: The Next Health Platform—or the Next Fitbit?

Oura Inc. (OURA) plans to offer 50.0 million shares on the Nasdaq Global Select Market at $40 to $44 per share, a $2.1 billion offering at the...

IPO Prophet

Oura (OURA) IPO: Three Numbers Investors Should Watch

Oura, Inc. plans to sell 50.0 million shares at an expected price of $40.00 to $44.00 per share and list on the Nasdaq Global Select Market under...

IPO Prophet

Oura (OURA US): Oura Steps Into the IPO Spotlight, Sets Terms With $14B+ Valuation Target

Oura combines rapid growth, recurring revenue, strong user metrics and notable cornerstone interest, making its $14B+ IPO a closely watched test...

IPO Boutique

TRex Bio (TRXB): Biotech Sector Remains Open as Lilly Backed Bio Sets Terms for IPO

TRex Bio brings a Treg-focused biotech platform to market with a Phase 1 lead asset, strong existing investors and Eli Lilly backing as biotech...

IPO Boutique

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)